RestructuringJun 18, 2026, 04:12 PM
enGene Updates Restructuring Costs, Ties $2.8M Equity Awards to FDA Milestones
AI Summary
enGene Holdings Inc. updated its estimated costs for the previously announced 50% workforce reduction, now expecting $5.7 to $6.4 million in cash restructuring costs and $4.7 to $5.0 million in non-cash stock-based compensation from accelerated vesting. The company also approved new performance-based equity retention awards, totaling up to $2.8 million in non-cash expense, which will vest upon FDA Biologics License Application (BLA) acceptance and regulatory approval for detalimogene by September 2027 and December 2028, respectively. CEO Ronald Cooper received a performance-based option award for 400,000 shares linked to these same milestones.
Key Highlights
- Estimated cash restructuring costs: $5.7 million to $6.4 million.
- Non-cash stock-based compensation from accelerated vesting: $4.7 million to $5.0 million.
- New performance-based equity retention awards: up to $2.8 million non-cash expense.
- Awards vest upon FDA BLA acceptance for detalimogene by September 30, 2027.
- Awards also vest upon FDA regulatory approval for detalimogene by December 31, 2028.
- CEO Ronald Cooper received 400,000 performance-based stock options at $1.75.
- Majority of restructuring expenses expected in the second half of 2026.
Price Impact
More from ENGN